GlassScriptPhysician profile
Holly B James
NPI 1144283482
$4,300.12
in general payments reported to CMS, 2019-2025
25 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $748 · 2023: $1,066 · 2024: $766 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,462 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,461.76 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,495.52 | 2022-2025 | |
| Pfizer INC. | $410.88 | 2023-2025 | |
| Lilly USA, LLC | $387.86 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $360.19 | 2025 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.73 | 2023-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $173.85 | 2022-2024 | |
| Novo Nordisk INC | $162.57 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $147.67 | 2022-2025 | Trintellix |
| Glaxosmithkline, LLC. | $133.84 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $111.88 | 2025 | Veozah |
| Exact Sciences Corporation | $111.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.27 | 2022-2025 | Jardiance |
| Daiichi Sankyo INC. | $68.97 | 2023-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $61.61 | 2022 | |
| Axsome Therapeutics, INC. | $58.73 | 2025 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $51.78 | 2025 | Zembrace Symtouch |
| Biogen, INC. | $47.41 | 2025 | Leqembi, Skyclarys |
| Ironshore Pharmaceuticals INC. | $47.15 | 2024 | |
| Collegium Pharmaceutical, INC. | $45.00 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $42.00 | 2025 | Nuplazid |
| Insightec,INC | $26.18 | 2025 | Exablate |
| Neurocrine Biosciences, INC. | $23.75 | 2025 | |
| Noven Therapeutics, LLC | $23.37 | 2024 | Xelstrym |
| Corium, LLC | $20.52 | 2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $18.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.